Bessemer Group Inc. Acquires 9,573 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Bessemer Group Inc. increased its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 10.9% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 97,167 shares of the biopharmaceutical company's stock after acquiring an additional 9,573 shares during the quarter. Bessemer Group Inc.'s holdings in Gilead Sciences were worth $8,974,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the company. HHM Wealth Advisors LLC boosted its holdings in Gilead Sciences by 118.5% in the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company's stock valued at $26,000 after purchasing an additional 154 shares during the period. YANKCOM Partnership purchased a new stake in shares of Gilead Sciences in the fourth quarter worth $28,000. Decker Retirement Planning Inc. bought a new stake in Gilead Sciences during the fourth quarter valued at $29,000. Crews Bank & Trust purchased a new position in Gilead Sciences during the fourth quarter worth about $31,000. Finally, Stephens Consulting LLC increased its stake in Gilead Sciences by 325.0% in the 4th quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company's stock worth $31,000 after acquiring an additional 260 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors.

Gilead Sciences Stock Down 1.1 %

GILD traded down $1.21 during trading on Tuesday, reaching $105.29. The stock had a trading volume of 3,258,892 shares, compared to its average volume of 7,479,928. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24. The stock's 50 day moving average is $108.48 and its two-hundred day moving average is $97.05. The company has a market capitalization of $131.10 billion, a price-to-earnings ratio of 284.57, a P/E/G ratio of 0.71 and a beta of 0.32. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $119.96.

Remove Ads

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, topping analysts' consensus estimates of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. As a group, analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, March 28th. Stockholders of record on Friday, March 14th were issued a dividend of $0.79 per share. This is an increase from Gilead Sciences's previous quarterly dividend of $0.77. This represents a $3.16 dividend on an annualized basis and a dividend yield of 3.00%. The ex-dividend date was Friday, March 14th. Gilead Sciences's dividend payout ratio is presently 854.05%.

Insider Activity at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 142,180 shares of the firm's stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $97.22, for a total value of $13,822,739.60. Following the sale, the chief financial officer now owns 129,873 shares in the company, valued at approximately $12,626,253.06. This trade represents a 52.26 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders have sold 302,785 shares of company stock valued at $30,503,250 over the last ninety days. Insiders own 0.16% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the company. Oppenheimer boosted their price objective on Gilead Sciences from $115.00 to $132.00 and gave the stock an "outperform" rating in a report on Tuesday, March 4th. DZ Bank raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $108.00 price target for the company in a research note on Thursday, February 13th. Needham & Company LLC restated a "hold" rating on shares of Gilead Sciences in a research report on Wednesday, February 12th. The Goldman Sachs Group upped their target price on shares of Gilead Sciences from $85.00 to $96.00 and gave the stock a "neutral" rating in a research report on Wednesday, February 12th. Finally, Royal Bank of Canada raised their price target on Gilead Sciences from $84.00 to $90.00 and gave the company a "sector perform" rating in a research report on Wednesday, February 12th. Eleven investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have given a strong buy rating to the stock. Based on data from MarketBeat, Gilead Sciences presently has an average rating of "Moderate Buy" and a consensus price target of $105.12.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.